KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Revenue (2016 - 2025)

Historic Revenue for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $164.9 million.

  • Travere Therapeutics' Revenue rose 16210.53% to $164.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $435.8 million, marking a year-over-year increase of 11422.14%. This contributed to the annual value of $233.2 million for FY2024, which is 6054.68% up from last year.
  • Travere Therapeutics' Revenue amounted to $164.9 million in Q3 2025, which was up 16210.53% from $114.4 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Revenue ranged from a high of $164.9 million in Q3 2025 and a low of -$158.2 million during Q4 2021
  • Its 5-year average for Revenue is $44.6 million, with a median of $45.1 million in 2023.
  • In the last 5 years, Travere Therapeutics' Revenue crashed by 41037.99% in 2021 and then soared by 16210.53% in 2025.
  • Over the past 5 years, Travere Therapeutics' Revenue (Quarter) stood at -$158.2 million in 2021, then surged by 118.54% to $29.3 million in 2022, then surged by 53.58% to $45.1 million in 2023, then skyrocketed by 65.98% to $74.8 million in 2024, then skyrocketed by 120.44% to $164.9 million in 2025.
  • Its last three reported values are $164.9 million in Q3 2025, $114.4 million for Q2 2025, and $81.7 million during Q1 2025.